SK183499A3 - Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma - Google Patents

Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma Download PDF

Info

Publication number
SK183499A3
SK183499A3 SK1834-99A SK183499A SK183499A3 SK 183499 A3 SK183499 A3 SK 183499A3 SK 183499 A SK183499 A SK 183499A SK 183499 A3 SK183499 A3 SK 183499A3
Authority
SK
Slovakia
Prior art keywords
cycloalkyl
alkyl
prostaglandin
aryl
ester
Prior art date
Application number
SK1834-99A
Other languages
English (en)
Slovak (sk)
Inventor
Johan Stjernschantz
Bahram Resul
Staffan Lake
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK183499(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Publication of SK183499A3 publication Critical patent/SK183499A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK1834-99A 1997-07-11 1998-07-10 Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma SK183499A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702706A SE9702706D0 (sv) 1997-07-11 1997-07-11 Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
PCT/SE1998/001368 WO1999002165A1 (en) 1997-07-11 1998-07-10 Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma

Publications (1)

Publication Number Publication Date
SK183499A3 true SK183499A3 (en) 2000-07-11

Family

ID=20407743

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1834-99A SK183499A3 (en) 1997-07-11 1998-07-10 Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma

Country Status (19)

Country Link
EP (1) EP1014991A1 (ja)
JP (1) JP2002509543A (ja)
KR (1) KR20010021682A (ja)
CN (1) CN1169528C (ja)
AU (1) AU739828B2 (ja)
BR (1) BR9815501A (ja)
CA (1) CA2294779A1 (ja)
HK (1) HK1029942A1 (ja)
HU (1) HUP0003106A3 (ja)
IL (1) IL133871A (ja)
IS (1) IS5333A (ja)
NO (1) NO20000062D0 (ja)
NZ (1) NZ501834A (ja)
PL (1) PL337940A1 (ja)
RU (1) RU2207858C2 (ja)
SE (1) SE9702706D0 (ja)
SK (1) SK183499A3 (ja)
TR (1) TR200000008T2 (ja)
WO (1) WO1999002165A1 (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9803761D0 (sv) * 1998-11-04 1998-11-04 Synphora Ab Method to avoid increased iridial pigmentation during prostaglandin treatment
EP1159266B1 (en) 1999-03-05 2004-11-03 Duke University C-16 unsaturated fp-selective prostaglandins analogs
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US6531504B2 (en) * 2001-05-17 2003-03-11 Allergan, Inc. Prostanoic acid derivatives as agents for lowering intraocular pressure
GB0112699D0 (en) 2001-05-24 2001-07-18 Resolution Chemicals Ltd Process for the preparation of prostglandins and analogues thereof
US6713268B2 (en) * 2001-06-26 2004-03-30 Allergan, Inc. Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
AU2003299137A1 (en) * 2002-09-16 2004-04-23 Texas Tech University System Inhibition of metallo-beta-lactamase
GB0501192D0 (en) 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
PL212658B1 (pl) * 2005-04-18 2012-11-30 Inst Farmaceutyczny Sposób otrzymywania pochodnych 13,14-dihydro-PGF<sub>2</sub><sub>α</sub>
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
JPWO2009133863A1 (ja) 2008-04-28 2011-09-01 国立大学法人浜松医科大学 Ｅｐ１アゴニストを含有してなる免疫増強剤
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
EP3828172A1 (en) 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
AU2009354014B2 (en) * 2009-10-16 2014-08-28 Cayman Chemical Company, Incorporated Process for the preparation of F-series prostaglandins
KR102070567B1 (ko) 2012-03-28 2020-01-29 메르크 파텐트 게엠베하 바이시클릭 피라지논 유도체
JP2012246301A (ja) * 2012-08-10 2012-12-13 Cayman Chemical Co Inc Ｆ系プロスタグランジン類を調製する方法
ES2852377T3 (es) 2013-03-15 2021-09-13 Aerie Pharmaceuticals Inc Sales dimesilato de 4-(3-amino-1-(isoquinolin-6-ilamino)-1-oxopropan-2-il)bencilo, sus combinaciones con prostaglandinas y el uso de las mismas en el tratamiento de trastornos oculares
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
MX2019002396A (es) 2016-08-31 2019-07-08 Aerie Pharmaceuticals Inc Composiciones oftalmicas.
CN110506037A (zh) 2017-03-31 2019-11-26 爱瑞制药公司 芳基环丙基-氨基-异喹啉酰胺化合物
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132738A (en) * 1978-02-23 1979-01-02 Miles Laboratories, Inc. Preparation of 15-deoxy-16-hydroxyprostaglandins
WO1994008585A1 (en) * 1992-10-13 1994-04-28 Alcon Laboratories, Inc. Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma

Also Published As

Publication number Publication date
JP2002509543A (ja) 2002-03-26
AU739828B2 (en) 2001-10-18
NO20000062L (no) 2000-01-06
TR200000008T2 (tr) 2000-05-22
WO1999002165A1 (en) 1999-01-21
BR9815501A (pt) 2001-07-17
RU2207858C2 (ru) 2003-07-10
SE9702706D0 (sv) 1997-07-11
NO20000062D0 (no) 2000-01-06
EP1014991A1 (en) 2000-07-05
PL337940A1 (en) 2000-09-11
IL133871A0 (en) 2001-04-30
IL133871A (en) 2004-09-27
KR20010021682A (ko) 2001-03-15
HUP0003106A3 (en) 2002-12-28
CN1169528C (zh) 2004-10-06
CA2294779A1 (en) 1999-01-21
IS5333A (is) 2000-01-07
AU8368398A (en) 1999-02-08
CN1262623A (zh) 2000-08-09
HK1029942A1 (en) 2001-04-20
HUP0003106A2 (hu) 2001-01-29
NZ501834A (en) 2002-05-31

Similar Documents

Publication Publication Date Title
SK183499A3 (en) Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
FI92690B (fi) Menetelmä farmakologisesti aktiivisten 13,14-dihydro-17-fenyyli-18,19,20-trinor-PGF2 -alkyyliestereiden valmistamiseksi
EP1920764B2 (en) Fluprostenol isopropyl ester for use in the treatment of glaucoma and ocular hypertension
US6232344B1 (en) 13-Oxa prostaglandins for the treatment of glaucoma and ocular hypertension
US20030166729A1 (en) Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US20040198817A1 (en) Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
NO308993B1 (no) Middel for behandling av lever- og gallesykdommer samt forbindelser som kan anvendes i midlet
US20030181493A1 (en) Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6172109B1 (en) 13-Thia prostaglandins for use in glaucoma therapy
AU2139600A (en) Method and composition for treatment of female sexual dysfunction
JP2003531824A (ja) フルプロステノールおよび関連プロスタグランジンＦ２α類似体の内部１，１５−ラクトン、ならびに緑内障および眼高血圧の治療におけるそれらの使用
WO1995026729A1 (en) New prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
CZ200084A3 (cs) Prostaglandinové deriváty pro léčení glaukomu, bez vedlejších účinků
DK176053B1 (da) Prostaglandinderivater til behandling af glaukom eller foröget okulært tryk
MXPA00000403A (en) Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
MXPA99008203A (en) 13-thia prostaglandins for use in glaucoma therapy
IE892976A1 (en) Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
EP1300149A2 (en) Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension